Aganitha

Aganitha is a next-generation in silico company that partners with global biopharma, personal and homecare, and material science organizations to bring better medicines and products to market faster. By integrating high-throughput sciences with deep learning-based generative models, Aganitha goes beyond first-generation AI to uncover the why and how behind diseases, therapeutics, and formulations — spanning targets and biomarkers, small molecules, antibodies, enzymes, ASO, mRNA, gene therapies, CMC, biopolymers, surfactants, and consumer care formulations.

Recognizing that bringing a new drug to market requires $1–2 billion and 6–12 years, Aganitha leverages advances in scRNA, multiomics, long-read sequencing, structural biology, and first-principles-based chemistry to help biopharma R&D teams reduce time, lower costs, and improve probability of success. The company's offerings span customizable platforms, computational science services, and AI-powered products, all designed to drive transformation across the full drug discovery and development value chain.

Core Products

• Igniva™ — Agentic AI Workflows for Science: A suite of AI agents purpose-built for therapeutic design and research, developed on the foundation of 7+ years of global R&D collaborations. Igniva™ brings together agentic AI and generative AI to support complex drug discovery workflows.
• DISTILL™: An AI-powered single-cell omics platform designed to extract meaningful insights from complex single-cell data sets.
• DBTIPS™: An AI-curated platform providing disease and target dossiers to accelerate target identification and validation research.
• NGS DataWorks™: A solution supporting next-generation sequencing data processing and analysis within the target and biomarker research workflow.

Solutions Across the Drug Discovery Value Chain

• Target and Biomarker Research: Capabilities spanning genomics, transcriptomics, proteomics, and organoid research to identify and validate disease targets and biomarkers.
• Small Molecule Engineering: Includes virtual screening, covalent binder design, and PROTAC development to support small molecule drug discovery.
• Antibody Engineering: Comprehensive capabilities covering antibody characterization, de novo antibody generation, antibody optimization, antibody virtual screening, and antibody-drug conjugates (ADCs).
• RNA Therapies: Solutions for antisense oligonucleotide (ASO) therapies, mRNA platform development, and lipid nanoparticle (LNP) engineering.
• Gene Therapies: Computational support for gene therapy research and development.
• Peptide Modeling and Enzyme Engineering: Specialized modeling capabilities for peptide-based therapeutics and enzyme design.
• CMC (Chemistry, Manufacturing, and Controls): Solutions including stability analysis, reaction modeling, catalysis modeling, and solid form de-risking to support drug development and manufacturing.

Services Offered

• Large Language Model Services: Applying LLM technologies to scientific and biopharma R&D challenges.
• Computational Biology: Expert services in biological data analysis, multiomics, and disease biology to complement internal R&D teams.
• Computational Chemistry: Chemistry-focused computational services supporting molecular design, screening, and optimization.
• Technology and Cloud Services: DevOps-driven automation and cloud infrastructure services to support resource-intensive scientific computing.

Focus Areas

• Biopharma R&D: Therapeutic areas including immunology, rare diseases, oncology, and CNS disorders.
• Consumer Care R&D: Computational solutions for personal and homecare product formulation and development.

Why Aganitha

• Multi-domain expertise: A robust team combining biology, chemistry, AI/ML, DevOps, and cloud skills to deliver integrated solutions.
• Deep biopharma focus: Continuously developing solutions, frameworks, and building blocks across the entire drug research and development value chain.
• Strong solutions foundation: A reference architecture and computational platform enable rapid delivery of high-quality solutions, leveraging cloud infrastructure for intensive computing workloads.
• Agile and enterprise-grade delivery: Leadership that is hands-on and brings a blend of start-up agility and enterprise-scale management, combining technology and domain expertise.
• Client-centric engagement: Flexible engagement models that ensure clients retain intellectual property rights (IPR) and molecule licenses across all projects.
• Collaboration with research and informatics teams: Aganitha works closely with both research and informatics divisions within biopharma organizations, addressing role- and department-specific objectives through tailored technology, domain, and management approaches.

Powered by agentic AI, generative AI, computational biology, and computational chemistry, Aganitha provides biopharma and consumer care companies with the scientific depth and technological sophistication needed to accelerate discovery, reduce development risk, and bring transformative products to market more efficiently.